BeiGene, Ltd. (ONC)vsTenaya Therapeutics Inc (TNYA)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TNYA
Tenaya Therapeutics Inc
$0.76
+0.79%
HEALTHCARE · Cap: $163.01M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
TNYA
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for TNYA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TNYA
The strongest argument for TNYA centers on Price/Book, Debt/Equity.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TNYA
The primary concerns for TNYA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while TNYA is a value play — different risk/reward profiles.
TNYA carries more volatility with a beta of 3.23 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 28/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Tenaya Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tenaya Therapeutics Inc. is a clinical-stage biotechnology innovator committed to revolutionizing heart disease treatment through its proprietary engineered heart cell platform. The company is addressing significant unmet needs in cardiovascular medicine by developing advanced gene therapies and regenerative solutions, with a robust pipeline of candidates targeting various heart disease indications. Tenaya's scientific rigor and focus on patient outcomes position it as a compelling investment opportunity in the biopharmaceutical sector, appealing to institutional investors seeking to support advancements in cardiac care. Its strategic initiatives underscore the potential for impactful contributions to the evolving landscape of cardiovascular therapies.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?